Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

globe_newswire · 2026-08-21

ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.

Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。